The finding from this meta-analysis supports the observation that high NCL expression is associated with poor prognosis in cancer patients including ependymoma, hepatocellular carcinoma, non-small cell lung cancer, pancreatic ductal carcinoma, endometrial carcinoma, gastric cancer, and B cell lymphoma. This evidence concerns the gene NUCLEOLIN and hepatocellular carcinoma.